Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C W Olanow

Showing results (51-60 of 160) with videos related to

Pageof 16
Sort By:
Experimental Neurology|June 18, 2017
Clinical approaches to the development of a neuroprotective therapy for PDC W Olanow, K Kieburtz, R Katz
Movement Disorders : Official Journal of the Movement Disorder Society|June 5, 1998
Current status of selegiline as a neuroprotective agent in Parkinson's diseaseC W Olanow, C Mytilineou, W Tatton
The New England Journal of Medicine|July 14, 2001
Transplantation of embryonic dopamine neurons for severe Parkinson's diseaseC W Olanow, T Freeman, J Kordower
Lancet (London, England)|September 21, 2002
Levodopa: why the controversy?Y Agid, C W Olanow, Y Mizuno
Transactions of the American Neurological Association|January 1, 1979
The effect of salicylate on phenytoin pharmacokineticsC W Olanow, A Finn, C Prussak
Neurology|March 1, 1981
The effects of salicylate on the pharmacokinetics of phenytoinC W Olanow, A L Finn, C Prussak
Transactions of the American Neurological Association|January 1, 1973
A double-blind controlled study of MK-486 in Parkinson's diseaseA M Schwartz, C W Olanow, A Spencer
Neurology|January 15, 2000
Falling asleep at the wheel: motor vehicle mishaps in people taking pramipexole and ropiniroleC W Olanow, A H Schapira, T Roth
Journal of Neurochemistry|January 1, 1997
L-(-)-desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitroC Mytilineou, P M Radcliffe, C W Olanow
BMJ (Clinical Research Ed.)|March 16, 1996
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Patients taking selegeline may have received more levodopa than necessaryC W Olanow, J H Godbold, W Koller
Pageof 16

Showing results (51-60 of 160) with videos related to

Sort By:
Pageof 16
Experimental Neurology|June 18, 2017
Clinical approaches to the development of a neuroprotective therapy for PDC W Olanow, K Kieburtz, R Katz
Movement Disorders : Official Journal of the Movement Disorder Society|June 5, 1998
Current status of selegiline as a neuroprotective agent in Parkinson's diseaseC W Olanow, C Mytilineou, W Tatton
The New England Journal of Medicine|July 14, 2001
Transplantation of embryonic dopamine neurons for severe Parkinson's diseaseC W Olanow, T Freeman, J Kordower
Lancet (London, England)|September 21, 2002
Levodopa: why the controversy?Y Agid, C W Olanow, Y Mizuno
Transactions of the American Neurological Association|January 1, 1979
The effect of salicylate on phenytoin pharmacokineticsC W Olanow, A Finn, C Prussak
Neurology|March 1, 1981
The effects of salicylate on the pharmacokinetics of phenytoinC W Olanow, A L Finn, C Prussak
Transactions of the American Neurological Association|January 1, 1973
A double-blind controlled study of MK-486 in Parkinson's diseaseA M Schwartz, C W Olanow, A Spencer
Neurology|January 15, 2000
Falling asleep at the wheel: motor vehicle mishaps in people taking pramipexole and ropiniroleC W Olanow, A H Schapira, T Roth
Journal of Neurochemistry|January 1, 1997
L-(-)-desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitroC Mytilineou, P M Radcliffe, C W Olanow
BMJ (Clinical Research Ed.)|March 16, 1996
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Patients taking selegeline may have received more levodopa than necessaryC W Olanow, J H Godbold, W Koller
Pageof 16